Janus kinase inhibitors for the treatment of myeloproliferative neoplasms
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Janus kinase inhibitors for the treatment of myeloproliferative neoplasms
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 15, Issue 9, Pages 1265-1276
Publisher
Informa Healthcare
Online
2014-04-25
DOI
10.1517/14656566.2014.913024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clearing the path for MPN therapy monitoring
- (2013) R. A. Mesa BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
- (2012) S.-J. Zhang et al. BLOOD
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
- (2011) T. Klampfl et al. BLOOD
- Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
- (2011) T. Manshouri et al. CANCER RESEARCH
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
- (2011) A V Purandare et al. LEUKEMIA
- Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
- (2011) A Deshpande et al. LEUKEMIA
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
- (2011) Y Nakaya et al. Blood Cancer Journal
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
- (2009) K. Hussein et al. BLOOD
- Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
- (2009) F. P. S. Santos et al. BLOOD
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
- (2009) Mrinal M. Patnaik et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mining the possibilities behind RBC alloimmunization
- (2008) L. Cooling BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation